Results of a phase II clinical trial conducted at MD Anderson Cancer Center revealed combination targeted therapy, consisting of rituximab, lenalidomide, and ibrutinib, had an 84.6% overall response rate and 38.5% complete response rate when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma.
Chris Biggar, a 34-year-old from Ohio, had just landed his dream job working in R&D when he was diagnosed with stage 4 colon cancer.Â
